RU2006136089A - Производные эпотилона - Google Patents
Производные эпотилона Download PDFInfo
- Publication number
- RU2006136089A RU2006136089A RU2006136089/04A RU2006136089A RU2006136089A RU 2006136089 A RU2006136089 A RU 2006136089A RU 2006136089/04 A RU2006136089/04 A RU 2006136089/04A RU 2006136089 A RU2006136089 A RU 2006136089A RU 2006136089 A RU2006136089 A RU 2006136089A
- Authority
- RU
- Russia
- Prior art keywords
- dione
- benzimidazol
- dimethyl
- formula
- hydroxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- -1 16- (1,2-dimethyl-1H-benzimidazol-5-yl) -8-hydroxy-5,5,7,9-tetramethyloxycyclohexadec-13-en-2,6-dione Chemical compound 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- BNEVSCPIBMLZGL-PYGHBYHZSA-N (1r,5s,6s,7r,10s,14s,16s)-14-(1,2-dimethylbenzimidazol-5-yl)-6,10-dihydroxy-5,7,9,9-tetramethyl-13-oxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@H]2C[C@H]2C[C@H]1C1=CC=C(N(C)C(C)=N2)C2=C1 BNEVSCPIBMLZGL-PYGHBYHZSA-N 0.000 claims 1
- GEYOFQZSFIWPPK-BQYTYRMFSA-N (1s,3s,10r,11s,12s,16r)-3-(1,2-dimethylbenzimidazol-5-yl)-11-hydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound O1C(=O)CCC(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@H]1C1=CC=C(N(C)C(C)=N2)C2=C1 GEYOFQZSFIWPPK-BQYTYRMFSA-N 0.000 claims 1
- PIUCYHQFEORJGM-CMNJRJKDSA-N (1s,5s,6s,7r,10s,14s,16s)-14-(1,2-dimethylbenzimidazol-5-yl)-6,10-dihydroxy-5,7,9,9-tetramethyl-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@H]2O[C@H]2C[C@H]1C1=CC=C(N(C)C(C)=N2)C2=C1 PIUCYHQFEORJGM-CMNJRJKDSA-N 0.000 claims 1
- PINYKHFDYGYNDE-RFPOXKJFSA-N (1s,5s,6s,7r,14s,16s)-14-(1,2-dimethylbenzimidazol-5-yl)-6-hydroxy-5,7,9,9-tetramethyl-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound O1C(=O)CCC(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@H]2O[C@H]2C[C@H]1C1=CC=C(N(C)C(C)=N2)C2=C1 PINYKHFDYGYNDE-RFPOXKJFSA-N 0.000 claims 1
- RSTCBJVXMTXRPE-UHFFFAOYSA-N 1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O=C1CCCCCCC=CCCOC(=O)CCC1 RSTCBJVXMTXRPE-UHFFFAOYSA-N 0.000 claims 1
- PIUCYHQFEORJGM-UHFFFAOYSA-N 14-(1,2-dimethylbenzimidazol-5-yl)-6,10-dihydroxy-5,7,9,9-tetramethyl-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C1=CC=C(N(C)C(C)=N2)C2=C1 PIUCYHQFEORJGM-UHFFFAOYSA-N 0.000 claims 1
- BNEVSCPIBMLZGL-UHFFFAOYSA-N 14-(1,2-dimethylbenzimidazol-5-yl)-6,10-dihydroxy-5,7,9,9-tetramethyl-13-oxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2CC2CC1C1=CC=C(N(C)C(C)=N2)C2=C1 BNEVSCPIBMLZGL-UHFFFAOYSA-N 0.000 claims 1
- PINYKHFDYGYNDE-UHFFFAOYSA-N 14-(1,2-dimethylbenzimidazol-5-yl)-6-hydroxy-5,7,9,9-tetramethyl-13,17-dioxabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound O1C(=O)CCC(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C1=CC=C(N(C)C(C)=N2)C2=C1 PINYKHFDYGYNDE-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- LZWPOLSJFGLQCE-UHFFFAOYSA-N heptadecane-5,9-dione Chemical compound CCCCCCCCC(=O)CCCC(=O)CCCC LZWPOLSJFGLQCE-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0405898.8 | 2004-03-16 | ||
| GBGB0405898.8A GB0405898D0 (en) | 2004-03-16 | 2004-03-16 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006136089A true RU2006136089A (ru) | 2008-04-27 |
Family
ID=32117793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006136089/04A RU2006136089A (ru) | 2004-03-16 | 2005-03-15 | Производные эпотилона |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7825141B2 (enExample) |
| EP (3) | EP1730138A1 (enExample) |
| JP (1) | JP2007529455A (enExample) |
| KR (1) | KR20070006773A (enExample) |
| CN (2) | CN101805328A (enExample) |
| AU (1) | AU2005223325B2 (enExample) |
| BR (1) | BRPI0508874A (enExample) |
| CA (1) | CA2556915A1 (enExample) |
| GB (1) | GB0405898D0 (enExample) |
| RU (1) | RU2006136089A (enExample) |
| WO (1) | WO2005090335A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007016046A1 (de) * | 2007-03-30 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1440973A3 (de) | 1995-11-17 | 2004-10-20 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilonderivate, Herstellung und Mittel |
| DE19751027A1 (de) | 1996-11-20 | 1998-05-28 | Degussa | Arylsubstituierte aminoacylierte Phosphonsäuren und deren Halbester |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| IL135590A (en) | 1997-12-04 | 2003-09-17 | Bristol Myers Squibb Co | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| DE19856128A1 (de) | 1998-12-04 | 2000-06-15 | Volkswagen Ag | Verfahren und Einrichtung zum Lesen von Navigationsdaten |
| AU2795000A (en) * | 1998-12-22 | 2000-07-12 | Novartis Ag | Epothilone derivatives and their use as antitumor agents |
| SK287200B6 (sk) | 1999-02-22 | 2010-03-08 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie |
| BR0212107A (pt) | 2001-08-23 | 2004-08-24 | Novartis Ag | Análogos da ciclopropil e da ciclobutil epotilona |
| DK1483251T3 (da) | 2002-03-12 | 2010-04-12 | Bristol Myers Squibb Co | C3-cyano-epothilon-derivater |
| AU2003266961A1 (en) | 2002-08-02 | 2004-02-25 | Novartis Ag | Epothilone derivatives |
-
2004
- 2004-03-16 GB GBGB0405898.8A patent/GB0405898D0/en not_active Ceased
-
2005
- 2005-03-15 EP EP05716085A patent/EP1730138A1/en not_active Withdrawn
- 2005-03-15 CN CN201010150615A patent/CN101805328A/zh active Pending
- 2005-03-15 EP EP10180401A patent/EP2301940A1/en not_active Withdrawn
- 2005-03-15 CA CA002556915A patent/CA2556915A1/en not_active Abandoned
- 2005-03-15 CN CN2005800069311A patent/CN1926133B/zh not_active Expired - Fee Related
- 2005-03-15 KR KR1020067018936A patent/KR20070006773A/ko not_active Withdrawn
- 2005-03-15 WO PCT/EP2005/002756 patent/WO2005090335A1/en not_active Ceased
- 2005-03-15 RU RU2006136089/04A patent/RU2006136089A/ru not_active Application Discontinuation
- 2005-03-15 JP JP2007503276A patent/JP2007529455A/ja not_active Withdrawn
- 2005-03-15 EP EP10160012A patent/EP2213670A3/en not_active Withdrawn
- 2005-03-15 BR BRPI0508874-7A patent/BRPI0508874A/pt not_active IP Right Cessation
- 2005-03-15 US US10/591,921 patent/US7825141B2/en not_active Expired - Fee Related
- 2005-03-15 AU AU2005223325A patent/AU2005223325B2/en not_active Ceased
-
2010
- 2010-09-21 US US12/886,819 patent/US20110009459A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110009459A1 (en) | 2011-01-13 |
| CA2556915A1 (en) | 2005-09-29 |
| CN1926133B (zh) | 2010-06-23 |
| EP2213670A3 (en) | 2010-11-24 |
| BRPI0508874A (pt) | 2007-09-04 |
| EP2301940A1 (en) | 2011-03-30 |
| CN101805328A (zh) | 2010-08-18 |
| EP2213670A2 (en) | 2010-08-04 |
| AU2005223325B2 (en) | 2009-09-10 |
| WO2005090335A1 (en) | 2005-09-29 |
| US20080114040A1 (en) | 2008-05-15 |
| CN1926133A (zh) | 2007-03-07 |
| JP2007529455A (ja) | 2007-10-25 |
| GB0405898D0 (en) | 2004-04-21 |
| KR20070006773A (ko) | 2007-01-11 |
| US7825141B2 (en) | 2010-11-02 |
| EP1730138A1 (en) | 2006-12-13 |
| AU2005223325A1 (en) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004522774A5 (enExample) | ||
| JP2004529904A5 (enExample) | ||
| RU2003128311A (ru) | Способ лечения резистентных опухолей с применением аналогов эпотилона | |
| RU2003128312A (ru) | Производные эпотилона, используемые для лечения резистентных опухлей | |
| JP2005527576A5 (enExample) | ||
| JP2001507716A5 (enExample) | ||
| RU2003130377A (ru) | Комбинация аналогов эпотилона и химиотерапевтических агентов для лечения пролиферативных заболеваний | |
| JP2002512239A5 (enExample) | ||
| PE20001546A1 (es) | Epolitonas c-21 modificadas | |
| ES2337134T3 (es) | Derivados de c3-ciano-epotilona. | |
| JP2009503105A5 (enExample) | ||
| RU2000132188A (ru) | Производные эпотилонов, их синтез и применение | |
| JP2003501474A5 (enExample) | ||
| JP2018509474A (ja) | インダン酢酸誘導体を用いる肝疾患の治療方法 | |
| JP2010527983A5 (enExample) | ||
| JP2003502367A5 (enExample) | ||
| WO2014017093A1 (ja) | ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩 | |
| RU2004129325A (ru) | Применение эпотилонов в лечении заболеваний мозга, ассоциированных с пролиферативными процессами | |
| WO2003077903A1 (en) | C12-cyano epothilone derivatives | |
| JP2014527542A (ja) | 骨がんの治療に使用するためまたは原発がん細胞の骨への転移性播種を予防するためのｐｉ３ｋ阻害剤 | |
| WO2011116663A1 (zh) | 2',2-双噻唑非核苷类化合物及其制备方法、药物组合物和作为肝炎病毒抑制剂的用途 | |
| RU2006136089A (ru) | Производные эпотилона | |
| JPWO2019200005A5 (enExample) | ||
| JP2007529455A5 (enExample) | ||
| JP2003521457A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100401 |